Trial Profile
A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients With Previously Treated Non-Squamous NSCLC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Jan 2023 Status changed from active, no longer recruiting to completed.
- 10 Sep 2022 Planned End Date changed from 31 Dec 2022 to 9 Sep 2023.
- 05 Jan 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.